1. Frey NV, Lazarus HM, Goldstein SC. Has allogeneic stem cell cryopreservation been given the “cold shoulder”? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation. Bone Marrow Transpl. 2006;38:399–405.
2. Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transpl. 2020;23:1–2.
3. Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) regarding the situation generated by the COVID-19 pandemic. 2020. https://www.ebmt.org/sites/default/files/2020-03/EBMT%20COVID-19%20guidelines%20v.4.3%20%282020-03-23%29.pdf.
4. Recommendations of the World Marrow Donor Association (WMDA) regarding donor medical suitability in the situation generated by the COVID-19 pandemic 2021. https://share.wmda.info/pages/viewpage.action?pageId=344866320.
5. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Biol Blood Marrow Transpl. 2020;26:1312–7.